Global Asthma Clinical Trial Pipeline Report 2021: Clinical Trial Stages, Drug Mechanism Classes, Companies, Short-term Launch Highlights


Dublin, May 28, 2021 (GLOBE NEWSWIRE) -- The "Global Asthma Clinical Trial Pipeline Highlights - 2021" report has been added to's offering.

sthma Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Asthma market. It covers emerging therapies for Asthma in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:
The report provides Asthma pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:
The report provides Asthma pipeline products by their dominant mechanism of action/drug class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

The report provides Asthma pipeline products by the company.

Short-term Launch Highlights:
Find out which Asthma pipeline products will be launched in the US and Ex-US till 2025.


  • Asthma phase 3 clinical trial pipeline products
  • Asthma phase 2 clinical trial pipeline products
  • Asthma phase 1 clinical trial pipeline products
  • Asthma preclinical research pipeline products
  • Asthma discovery stage pipeline products
  • Asthma pipeline products short-term launch highlights

Key Topics Covered:

1. Asthma Pipeline by Stages

2. Asthma Phase 3 Clinical Trial Insights

3. Asthma Phase 2 Clinical Trial Insights

4. Asthma Phase 1 Clinical Trial Insights

5. Asthma Preclinical Research Insights

6. Asthma Discovery Stage Insights

7. Appendix

For more information about this report visit


Contact Data